Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V116 in Pneumococcal Vaccine-Experienced Adults
NCT05420961Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Primary completion
- May 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal 21-valent conjugate vaccine in invasive pneumococcal disease (IPD) and Pneumococcal pneumonia (PP) (5 cohorts), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With Solicited Injection-site Adverse Events at 5 days, Percentage of Participants With Solicited Systemic Adverse Events at 5 days and 2 more. Started Jul 2022; status: completed.
02
Drugs
pneumococcal 21-valent conjugate vaccine
03
Conditions
invasive pneumococcal disease (IPD)Pneumococcal pneumonia (PP)
Beyond the preview
Go deeper on NCT05420961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05420961.